A collaboration among researchers in Israel and the United States has resulted in the discovery of a new pathway with broad implications for treating allergic diseases — particularly eosinophil-associated disorders. Researchers have discovered how this pathway kills eosinophils before they can cause havoc. Eosinophils are normal cellular blood components, but when the body produces too many eosinophils they can cause a variety of eosinophilic disorders.